SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE (SIBN) reported Q3 2025 results with strong top-line growth and improved profitability trends. Revenue was $48,656,000, up 20.6% from $40,340,000, driven largely by higher U.S. case volumes. Gross margin expanded to 79.8% from 79.1%, lifting gross profit to $38,846,000.
Operating expenses rose to $44,229,000, primarily from higher sales and marketing and general and administrative costs, resulting in a smaller operating loss of $5,383,000 versus $7,633,000 a year ago. Net loss narrowed to $4,566,000 compared with $6,575,000, and net loss per share improved to $0.11 from $0.16.
Liquidity remained solid with cash and cash equivalents of $26,487,000 and short-term investments of $119,257,000. Inventory increased to $35,727,000 to support demand. Long-term borrowings were $35,540,000. Shares outstanding were 43,391,254 as of November 4, 2025.
SI-BONE, Inc. (SIBN) announced board and governance updates. Director Daniel Wolf resigned from the Board on November 6, 2025, and the company stated his resignation was not due to any disagreement with the company or management. Following his departure, the Board size was reduced from nine to eight, and current director Thomas A. West was appointed to the Audit Committee.
SI-BONE and Mr. Wolf entered into a 12-month consulting agreement covering marketing, strategy, business development and other corporate matters. The agreement accelerates vesting of 8,675 restricted stock units granted to Mr. Wolf on June 5, 2025, making them fully vested as of November 6, 2025, and provides cash compensation at an hourly rate set in applicable statements of work. The company also furnished a press release announcing results for the quarter ended September 30, 2025 as Exhibit 99.1.
SI‑BONE (SIBN) director reported a routine insider transaction. On 11/03/2025, the reporting person sold 293 shares of common stock at a weighted average price of $14.8038. The filing states this was a sell‑to‑cover to satisfy tax withholding from vesting RSUs, not a discretionary trade.
Following the transaction, the filer beneficially owns 10,831 shares directly and 118,350 shares indirectly via a trust. The direct holdings include 10,307 shares issuable upon settlement of restricted stock units, each representing one share.
SI-BONE, Inc. (SIBN) reported insider sales by Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, on 10/02/2025. The Form 4 shows a total of 3,128 shares of common stock sold across multiple trades to satisfy tax withholding on vesting restricted stock units; these sales are described as a "sell to cover" and not discretionary. Reported weighted average prices per transaction are $14.255, $14.1053, and $14.2537, and the filing lists 256,556, 256,522, and 255,224 shares beneficially owned after each reported sale line. The filing also discloses 132,362 shares issuable on settlement of restricted stock units retained by the reporting person.
SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported selling a total of 3,311 shares of common stock on October 2, 2025, in open-market transactions at weighted average prices of $14.2237 and $14.1711 per share.
The company states these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and did not represent a discretionary trade by the CFO. After these transactions, Maheshwari directly holds 211,134 shares of common stock, including 150,203 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 10/02/2025, he sold 1,557 shares at a weighted average price of $14.2374 and 1,754 shares at a weighted average price of $14.27.
The filing states these were sell-to-cover sales to satisfy tax withholding upon RSU vesting and were not discretionary trades. Following the transactions, he beneficially owned 271,977 shares. This total includes 141,167 shares issuable upon settlement of restricted stock units, with each RSU representing one share.
Anthony J. Recupero, President, Commercial Ops of SI-BONE, Inc. (SIBN), reported routine sales on 08/18/2025 to cover tax withholding arising from vested restricted stock units. The Form 4 shows two disposition entries totaling 3,833 shares sold (2,126 and 1,707 shares) at weighted-average prices of $15.627 and $15.6134, executed in multiple trades within price ranges noted in the footnotes. After the reported transactions, the filing shows 275,288 shares beneficially owned and discloses 147,947 shares issuable upon settlement of outstanding restricted stock units. The filing identifies the sales as "sell to cover" for tax obligations and not discretionary trading.
Michael A. Pisetsky, SVP, Ops & Adm and Chief Legal Officer of SI-BONE, Inc. (SIBN), reported sales on 08/18/2025 that were executed to satisfy tax withholding obligations on vesting restricted stock units through a "sell-to-cover" process. The filing shows two non-derivative dispositions: 1,851 shares sold at a weighted-average price of $15.6524 and 1,478 shares sold at a weighted-average price of $15.6171, with transaction prices ranging from $15.49 to $15.80. After these transactions the reporting person beneficially owned 258,352 shares. The filing discloses that 138,504 of those shares are issuable upon settlement of restricted stock units, each representing a contingent right to one share.
Insider sale to cover taxes: SI-BONE Chief Financial Officer Anshul Maheshwari reported sales of common stock on 08/18/2025 to satisfy tax withholding on vested restricted stock units. The Form 4 shows two sell-to-cover transactions: 1,276 shares sold at a weighted average price of $15.5924 and 2,185 shares sold at a weighted average price of $15.5538, reducing beneficial ownership to 216,630 and 214,445 shares respectively as reported for each line. The report notes 156,983 shares remain issuable upon settlement of outstanding restricted stock units. The filing states these sales were non-discretionary and executed in multiple trades across price ranges disclosed in the footnotes.
SI-BONE insider sale tied to RSU tax withholding: Laura A. Francis, who serves as both Chief Executive Officer and a director, reported multiple dispositions of her common stock to satisfy tax withholding on vested restricted stock units. The transactions on 08/18/2025 consisted of five grouped sales totaling 11,343 shares disposed at weighted-average prices in the roughly $15.52–$15.83 range, producing the reported per-trade weighted averages shown. After these transactions the filing shows Ms. Francis directly beneficially owns 419,704 shares and indirectly owns 362,141 shares through The David & Laura Joint Rev Tr., with 396,297 shares included as shares issuable upon settlement of RSUs.